HS
RGNX icon

HighVista Strategies’s Regenxbio RGNX Stock Holding History

HighVista Strategies’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-29,696
Closed -$785K – 121
2022
Q3 		$785K Buy
29,696
+13,344
+82% +$396K 0.45% 59
2022
Q2 		$404K Buy
+16,352
New +$409K 0.24% 80
2022
Q1 		– Sell
-29,753
Closed -$973K – 96
2021
Q4 		$973K Buy
+29,753
New +$1.01M 0.77% 49

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

HighVista Strategies's RGNX Position: Q4 2022 in Review

HighVista Strategies sold out of Regenxbio (RGNX) in Q4 2022, closing a stake of 29,696 shares — an estimated $785K sold.

HighVista Strategies first reported a position in RGNX in Q4 2021 and held it in 3 quarters. The position peaked at $973K in Q4 2021. 180 funds tracked by Wall St. Rank hold RGNX as of Q4 2022.

  • HighVista Strategies reported no remaining Regenxbio position as of Q4 2022 after selling out during the quarter.
  • HighVista Strategies sold 29,696 Regenxbio shares in Q4 2022, an estimated $785K.
  • HighVista Strategies first reported a position in Regenxbio in Q4 2021 and held it in 3 quarters.
  • HighVista Strategies's Regenxbio position peaked at $973K in Q4 2021.
  • 180 funds tracked by Wall St. Rank held Regenxbio as of Q4 2022.

Based on HighVista Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.